First round of lung cancer screening among patients with atheromatous cardiovascular disease exposed to tobacco: a prospective cohort study
Abstract
Introduction: Identification of populations eligible for lung cancer screening (LCS) is a priority question in this field. The primary objective of this study was to quantify lung cancer prevalence after a first round of LCS among patients with history of atheromatous cardiovascular disease (aCVD) and tobacco exposure. Methods: We performed a prospective bi-centric descriptive quantification of lung cancer prevalence among patients aged 45-75 years old with minimal history of 10 years of daily smoking and aCVD who underwent a chest computed tomography (CT) in an intend to screen. We also described lung cancer stage at diagnosis and treatments, we evaluated the eligibility of our population to the National Lung Screening Trial (NLST) and the Dutch-Belgian randomized controlled trial (NELSON) and described main quality metrics of LCS clinical path. Results: Among 505 participants who underwent a chest CT 159/505 (31%) did not met NLST nor NELSON eligibility criteria, 19/505 (3.8%) participants presented a positive screening. We diagnosed 16 cancers in 15 patients resulting in a LC prevalence of 2.97% (15/505). Among 16 lung cancers, 11 were stage I or II (75%). All patients with lung cancer received specific treatments including 12 surgeries alone, 2 surgeries with adjuvant systemic therapy, 1 radiation with systemic therapy and one systemic therapy alone; there was no postoperative severe morbidity (i.e. Clavien Dindo ≥ 3).
Conclusions: Our exploratory descriptive prospective study suggests that age 45-75 years-old, daily smoking for 10 years and aCVD may be evaluated in future studies as additional LCS eligibility criteria to existing LCS eligibility criteria.
Related
- Cost and transportation barrier trends related to Affordable Care Act among cancer survivors and atherosclerotic cardiovascular disease patients
- Federated deep learning for privacy-preserving cardiovascular disease risk prediction
- Regarding the inference of causality in observational non-controlled studies. Comment on “Assessment of sexual function and its association with quality of life and disease severity in patients with atopic dermatitis”
- Nonlinear trajectories of lung function recovery in patients with pulmonary disease: empirical evaluation of longitudinal modeling approaches
- Prediction of oxygen uptake at peak exercise in patients with inflammatory bowel disease using submaximal cardiopulmonary exercise testing and the steep ramp test as a practical field test
BibTeX
@article{armand2026first,
title = {{First round of lung cancer screening among patients with atheromatous cardiovascular disease exposed to tobacco: a prospective cohort study}},
author = {Elsa Armand and Clarisse Buton and Caroline Caramella and Paul Habert and Ilyes Hamouda and Zeinab Hamidou and Justin Issard and Pauline Pradère and Gaëlle Dauriat and Sacha Mussot and Delphine Mitilian and Océane Hache and Lilia Lamrani and Jérôme Le Pavec and Marc Zins and Marine Fidelle and Johan Pluvy and Geoffrey Brioude and Alban Todesco and Jean-Baptiste Lovato and Julie Tronchetti and Herve Dutau and Laurent Greillier and Jean-Yves Gaubert and Alexis Jacquier and Delphine Trousse and Xavier-Benoit D’journo and Pascal-Alexandre Thomas and Elie Fadel and Stephan Haulon and Dominique Fabre and Saïd Ghostine and Martin Kloeckner and Pamela Abdayem and Guido Kroemer and Laurence Zitvogel and Benjamin Besse and Olaf Mercier and David Boulate},
journal = {Respiratory Medicine and Research},
year = {2026},
month = oct,
doi = {10.1016/j.resmer.2026.101324},
url = {https://inria.hal.science/hal-05785405v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - First round of lung cancer screening among patients with atheromatous cardiovascular disease exposed to tobacco: a prospective cohort study
AU - Elsa Armand
AU - Clarisse Buton
AU - Caroline Caramella
AU - Paul Habert
AU - Ilyes Hamouda
AU - Zeinab Hamidou
AU - Justin Issard
AU - Pauline Pradère
AU - Gaëlle Dauriat
AU - Sacha Mussot
AU - Delphine Mitilian
AU - Océane Hache
AU - Lilia Lamrani
AU - Jérôme Le Pavec
AU - Marc Zins
AU - Marine Fidelle
AU - Johan Pluvy
AU - Geoffrey Brioude
AU - Alban Todesco
AU - Jean-Baptiste Lovato
AU - Julie Tronchetti
AU - Herve Dutau
AU - Laurent Greillier
AU - Jean-Yves Gaubert
AU - Alexis Jacquier
AU - Delphine Trousse
AU - Xavier-Benoit D’journo
AU - Pascal-Alexandre Thomas
AU - Elie Fadel
AU - Stephan Haulon
AU - Dominique Fabre
AU - Saïd Ghostine
AU - Martin Kloeckner
AU - Pamela Abdayem
AU - Guido Kroemer
AU - Laurence Zitvogel
AU - Benjamin Besse
AU - Olaf Mercier
AU - David Boulate
PY - 2026
DA - 2026/10/08
JO - Respiratory Medicine and Research
DO - 10.1016/j.resmer.2026.101324
UR - https://inria.hal.science/hal-05785405v1
AB - Introduction: Identification of populations eligible for lung cancer screening (LCS) is a priority question in this field. The primary objective of this study was to quantify lung cancer prevalence after a first round of LCS among patients with history of atheromatous cardiovascular disease (aCVD) and tobacco exposure. Methods: We performed a prospective bi-centric descriptive quantification of lung cancer prevalence among patients aged 45-75 years old with minimal history of 10 years of daily smoking and aCVD who underwent a chest computed tomography (CT) in an intend to screen. We also described lung cancer stage at diagnosis and treatments, we evaluated the eligibility of our population to the National Lung Screening Trial (NLST) and the Dutch-Belgian randomized controlled trial (NELSON) and described main quality metrics of LCS clinical path. Results: Among 505 participants who underwent a chest CT 159/505 (31%) did not met NLST nor NELSON eligibility criteria, 19/505 (3.8%) participants presented a positive screening. We diagnosed 16 cancers in 15 patients resulting in a LC prevalence of 2.97% (15/505). Among 16 lung cancers, 11 were stage I or II (75%). All patients with lung cancer received specific treatments including 12 surgeries alone, 2 surgeries with adjuvant systemic therapy, 1 radiation with systemic therapy and one systemic therapy alone; there was no postoperative severe morbidity (i.e. Clavien Dindo ≥ 3). Conclusions: Our exploratory descriptive prospective study suggests that age 45-75 years-old, daily smoking for 10 years and aCVD may be evaluated in future studies as additional LCS eligibility criteria to existing LCS eligibility criteria.
SN - 2590-0412
ER -